Conference Description
Understanding Atherosclerosis in Patients with Diabetes: Prediction, Progression, Prevention
June 5, 2007
Morton's Steakhouse
501 Elm Street
Dallas, Texas
Tell a friend about this conference
Download the brochure for this conference
CME Credits 2.0*
Nonrefundable registration fee: $0.
Target Audience: Physicians, nurse practitioners, and physician assistants who have a high
interest in treating patients with diabetes.
Program Summary:
This two-hour CME activity for practitioners treating diabetes will review the
pathophysiology and current clinical trials that impact the development of
coronary atherosclerosis in patients with type 2 diabetes. Attendees will gain
a clearer understanding of the risk factors for cardiovascular disease in
diabetes. The program will review recent trials addressing the management
of diabetic dyslipidemia, the prevention of macrovascular disease, and the
role of TZD medications in primary prevention of diabetes and secondary
prevention of atherosclerosis. Following the presentation there will be a
question and answer session.
Learning Objectives:
At the conclusion of this program, attendees will be able to:
- demonstrate a clearer understanding of the conventional risk factors for cardiovascular disease in diabetes
- discuss recent trials addressing the management of diabetic dyslipidemia
- explain the potential for secondary prevention of macrovascular disease in diabetics
- evaluate the role of the TZD medications in primary prevention of diabetes, and secondary prevention of atherosclerosis
Agenda:
| 6:30-7:00 pm |
|
Welcome and Registration |
| 7:00-8:00 |
|
Understanding Atherosclerosis
in Patients with Diabetes:
Prediction, Progression,
Prevention
|
| 8:00-9:00 |
|
Discussion, Question and Answer |
Faculty:
One of the following faculty members will present:
Patrick J. Boyle, MD
Professor of Medicine
University of New Mexico
Albuquerque, NM
John Buse, MD
Chief, Division of General Medicine and Clinical Epidemiology
University of North Carolina
School of Medicine
Chapel Hill, NC
Byron Hoogwerf, MD
Cleveland Clinic
Department of Endocrinology
Cleveland, OH
Mark Stolar, MD
Associate Professor of Clinical Medicine
Northwestern University Medical School
Chicago, IL
*Continuing Education Information
Application for CME credit has been filed with the American Academy of Family
Physicians. Determination of credit is pending.
This activity has been planned and implemented in accordance with the Essentials
and Standards of the Accreditation Council for Continuing Medical Education
(ACCME) through the joint sponsorship of the University of Massachusetts Medical
School (UMMS) and the National Association for Continuing Education. The
University of Massachusetts Medical School is accredited by the Accreditation
Council for Continuing Medical Education (ACCME) to provide continuing medical
education for physicians. The University of Massachusetts Medical School designates
this educational activity for a maximum of 2 AMA PRA Category I Credit(s)TM.
Physicians should only claim credit commensurate with the extent of their participation
in the activity.
Under the auspices of the University of Massachusetts Medical School Office of
Continuing Education this offering meets the requirements for 2.4 contact hours, as
specified by the Massachusetts Board of Registration in Nursing (244- CMR 5.04).
Each nurse should claim only those hours of credit that he/she actually spent in the
educational activity.
Policy on Faculty and Provider Disclosure: It is the policy of the University of
Massachusetts Medical School to ensure fair balance, independence, objectivity and
scientific rigor in all activities. All faculty participating in CME activities sponsored
by the University of Massachusetts Medical School are required to present evidencedbased
data, identify and reference off-label product use and disclose all relevant
financial relationships with those supporting the activity or others whose products or
services are discussed. Faculty disclosure will be provided in the activity materials.
This program is supported through an unrestricted educational grant from Takeda Pharmaceuticals North America.
|
